Royce & Associates LP Grows Stock Position in Simulations Plus, Inc. (NASDAQ:SLP)

Royce & Associates LP boosted its position in Simulations Plus, Inc. (NASDAQ:SLP) by 56.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 371,797 shares of the technology company’s stock after purchasing an additional 134,381 shares during the quarter. Royce & Associates LP owned about 1.85% of Simulations Plus worth $10,369,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC boosted its holdings in shares of Simulations Plus by 390.6% during the 3rd quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock worth $911,000 after purchasing an additional 22,669 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in Simulations Plus during the fourth quarter worth $719,000. Geode Capital Management LLC grew its holdings in Simulations Plus by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock valued at $14,367,000 after buying an additional 18,924 shares in the last quarter. State Street Corp increased its stake in shares of Simulations Plus by 4.7% in the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after acquiring an additional 28,953 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Simulations Plus by 106.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock worth $1,517,000 after acquiring an additional 24,371 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Price Performance

Shares of SLP stock opened at $26.23 on Tuesday. Simulations Plus, Inc. has a 1-year low of $24.00 and a 1-year high of $51.22. The firm has a market cap of $527.01 million, a PE ratio of 65.58 and a beta of 0.89. The company has a 50-day moving average of $31.57 and a two-hundred day moving average of $31.14.

Analysts Set New Price Targets

SLP has been the subject of a number of analyst reports. William Blair reissued an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp increased their price target on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Insider Transactions at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the sale, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 19.40% of the company’s stock.

Simulations Plus Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.